STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial

This publication has 22 references indexed in Scilit:

• Speeding up the Evaluation of New Agents in Cancer
  JNCI: Journal of the National Cancer Institute, 2008
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
  Clinical Cancer Research, 2008
• Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
  Journal of Clinical Oncology, 2008
• COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial
  The Lancet Oncology, 2007
• Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)
  JNCI: Journal of the National Cancer Institute, 2007
• A retrospective study of the time to clinical endpoints for advanced prostate cancer
  BJU International, 2005
• Differential Inhibition of Invasion and Proliferation by Bisphosphonates: Anti-Metastatic Potential of Zoledronic Acid in Prostate Cancer
  European Urology, 2004
• SURVIVAL OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA
  Journal of Urology, 2004
• A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate Cancer
  Mayo Clinic Proceedings, 2002
• A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
  New England Journal of Medicine, 1989